A detailed history of Mangrove Partners transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Mangrove Partners holds 8,729,720 shares of MREO stock, worth $33.3 Million. This represents 4.66% of its overall portfolio holdings.

Number of Shares
8,729,720
Previous 8,752,893 0.26%
Holding current value
$33.3 Million
Previous $31.5 Million 13.87%
% of portfolio
4.66%
Previous 3.54%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.45 - $4.87 $79,946 - $112,852
-23,173 Reduced 0.26%
8,729,720 $35.9 Million
Q4 2023

Feb 14, 2024

BUY
$1.19 - $2.42 $3.83 Million - $7.8 Million
3,221,346 Added 58.24%
8,752,893 $20.2 Million
Q2 2023

Aug 14, 2023

BUY
$0.79 - $1.43 $4.37 Million - $7.91 Million
5,531,547 New
5,531,547 $7.3 Million

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $476M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Mangrove Partners Portfolio

Follow Mangrove Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

News

Stay updated on Mangrove Partners with notifications on news.